Sexual health

Research only

These are not on an FDA list that allows compounding, or we have not yet read their status. We cover the research on them and link no seller.

• Kisspeptin

  Research only

  Kisspeptin-10 is in 503A Category 2 (bulk drug substances that raise significant safety risks), placed there September 29, 2023 and still listed in the May 14, 2026 update. FDA cites a possible risk of immunogenicity and peptide-related impurities, and says it has no, or only limited, safety information for the proposed routes.

  Source:FDA document, read September 2026.Also:FDA, safety risks of certain bulk drug substances (Category 2 date and reason)

  3 sellers we track list it; none publishes a price yet.

• Oxytocin

  Status not yet reviewed

  We have not yet read this compound’s regulatory status, so we list no seller for it.

  10 sellers we track list it; none publishes a price yet.

• Melanotan II

  Research only

  On no FDA compounding list. Neither "melanotan" in any spelling nor the related approved substance afamelanotide appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025).

  Source:FDA document, read September 2026.Also:FDA 503B bulk drug substances categories (updated March 21, 2025)

  1 seller we track list it; none publishes a price yet.

Research on sexual health

1. Vyleesi Drug Interactions: Birth Control, Naltrexone and AlcoholVyleesi is injected but can slow how pills are absorbed. The label names oral naltrexone as the one drug to avoid, tested two birth control hormones without flagging them, and studied alcohol.
2. Melanotan 2: what the research shows, and what went wrongMelanotan II is not inert — a controlled study produced erections in 12 of 19 injections. The reasons to avoid it are the priapism, the renal infarction and the unregulated vial.
3. Ozempic and Sex Drive: What the Evidence ShowsThe label says nothing about it. Meta-analyses in men find testosterone and erectile scores improving, one records study found erectile dysfunction diagnosed 26% more often until the authors calibrated it away, and the evidence in women is case reports.
4. Peptides for Sex Drive: PT-141, Kisspeptin and Oxytocin in the TrialsOne of these cleared a regulator. Bremelanotide raised desire scores 0.35 points above placebo across 1,267 women. Kisspeptin has two randomized trials in low desire whose endpoint was a brain scan, and intranasal oxytocin did no better than placebo in 30 women.
5. Oxytocin Nasal Spray: What Human Trials of the Intranasal Dose FoundA crossover trial in 30 women with sexual dysfunction found intranasal oxytocin did no better than placebo on any score. In 29 couples, a single dose left desire, arousal and erection unchanged while raising orgasm intensity and contentment.
6. Vyleesi Reviews: What Women in the Trials Reported, and What the Numbers ShowIn exit interviews, women who took Vyleesi described more desire and arousal. On the trials' scales the gains over placebo were small, satisfying sexual events did not change, and about 4 in 10 stopped early, often for nausea.
7. How Long Does PT 141 Last? Four Clocks, and the One Nobody Has TimedPT-141 peaks in the blood within an hour, and a standard half-life estimate puts it largely cleared within about half a day. How long its effect on desire lasts after a dose is, by the label's own account, unknown.
8. Bremelanotide (PT-141): The FDA Approval and What the Trials ShowedBremelanotide is approved for low sexual desire in premenopausal women. Two phase 3 trials found a modest benefit, and 40% of women on it reported nausea.
9. Bremelanotide Side Effects: Nausea, Blood Pressure and Skin DarkeningNausea in 40% of women, a brief blood pressure rise after every dose, and skin darkening that depends heavily on how often it is taken. What the Vyleesi label and trials report.
10. Kisspeptin: What Human Studies Show About Libido and Reproductive HormonesSingle kisspeptin infusions changed brain responses to sexual cues in men and women with low desire, and raised reproductive hormones. It is not approved, and the FDA flags kisspeptin-10.
11. PT 141 Dosage: The Vyleesi Label's 1.75 mg Dose and What Trials TestedThe label states one dose, 1.75 mg under the skin at least 45 minutes ahead, with limits of one a day and eight a month. Where that dose came from, and what it caused.
12. PT 141 for Men: What the Erectile Dysfunction Trials FoundBremelanotide was first tested in men, then approved only for women. The male evidence is a few short lab studies of erections, and one larger trial its journal has flagged.
13. PT-141 Nasal Spray: Why Intranasal Bremelanotide Was Dropped in TrialsBremelanotide was first tested as a nasal spray. Its developer dropped the route over blood pressure rises and uneven absorption, and the approved product is an injection.